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Abstract
It is generally accepted that the de-differentiation of smooth muscle cells (SMCs) from contractile 
to proliferative/synthetic phenotype has an important role during vascular remodeling and 
diseases. Here we provide evidence that challenges this theory. We identify a new type of 
multipotent vascular stem cell (MVSC) in blood vessel wall. MVSCs express markers including 
Sox17, Sox10 and S100β, are cloneable, have telomerase activity, and can differentiate into neural 
cells and mesenchymal stem cell (MSC)-like cells that subsequently differentiate into SMCs. On 
the other hand, we use lineage tracing with smooth muscle myosin heavy chain as a marker to 
show that MVSCs and proliferative or synthetic SMCs do not arise from the de-differentiation of 
mature SMCs. Upon vascular injuries, MVSCs, instead of SMCs, become proliferative, and 
MVSCs can differentiate into SMCs and chondrogenic cells, thus contributing to vascular 
remodeling and neointimal hyperplasia. These findings support a new hypothesis that the 
differentiation of MVSCs, rather than the de-differentiation of SMCs, contributes to vascular 
remodeling and diseases.
Vascular diseases are a leading cause of death in many countries. The development of 
vascular diseases, such as intimal hyperplasia and atherosclerosis, involves proliferation and 
migration of vascular cells1–4. Vascular smooth muscle cells (SMCs) are the predominant 
cell type in the tunica media of the blood vessel wall. Studies from many laboratories have 
shown that cultured SMCs and SMCs in the neointima “loose” the expression of smooth 
muscle myosin heavy chain (SM-MHC), a marker of contractile SMCs, and become 
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proliferative and synthetic 5–10. A widely accepted explanation is that SMCs have 
phenotypic plasticity and that mature or contractile SMCs can de-differentiate into 
proliferative and synthetic SMCs 4, 11–13. However, this de-differentiation process has not 
been directly demonstrated by tracking the fate of mature or contractile SMCs.
Over the past decade, several types of SMC-related vascular progenitors in the blood vessels 
have been identified 14, 15. In the media layer, mesenchymal stem cells (MSC)-like cells can 
be isolated from SMC population, which express CD29 and CD44, and show multilineage 
potential for osteogenic and chondrogenic differentiation but not for adipogenic 
differentiation 16, 17. In adventitia, Sca-1+ progenitors can differentiate into SMCs and 
contribute to atherosclerosis of vein grafts in ApoE-deficient mice 18. In addition, CD146+ 
perivascular MSC-like cells demonstrate osteogenic, chondrogenic and adipogenic 
potentials 19. Furthermore, evidence exists that vascular endothelial cells (EC) can be 
converted into MSC-like cells by an activin-like kinase-2 receptor-dependent mechanism 20. 
However, the characterization of these vascular progenitors is limited to non-specific surface 
markers, and whether these vascular progenitors have an important role in the generation of 
proliferative or synthetic SMCs and the development of vascular diseases remains unclear.
In this study, we isolate cells from the media layer of the blood vessel wall and identify a 
new type of multipotent vascular stem cell (MVSC) expressing markers such as Sox17, 
Sox10, S100β and neural filament-medium polypeptide (NFM). MVSCs can differentiate 
into MSC-like cells and subsequently SMCs. In addition, MVSCs and MSC-like cells 
respond differently to vascular growth factors. Importantly, lineage-tracing experiments 
show that MVSCs and proliferative or synthetic SMCs are not derived from mature SMCs. 
Upon vascular injury, MVSCs become proliferative and contribute significantly to vascular 
remodeling and neointima formation. These findings define a novel MVSC-SMC 
differentiation pathway, and support a new hypothesis that the differentiation of MVSCs 
instead of the de-differentiation of SMCs contributes to vascular remodeling and diseases.
Results
Identification and characterization of rat MVSCs
First, we verified the existence of SM-MHC− cells in the tunica media layer by 
immunostaining the cross-sections of carotid arteries from Sprague Dawley (SD) rats for 
smooth muscle α-actin (SMA) and SM-MHC. As shown in Supplementary Fig. S1, the 
majority of cells inside the elastic lamina layers were mature and contractile SMCs 
(SMA+/SM-MHC+), whereas a small population (less than 10%) were negative for SM-
MHC in the media layer.
We then isolated and characterized the cells from the tunica media of carotid arteries of SD 
rats. Using enzymatic digestion, we obtained a mixed cell population including both mature 
SMCs and non-SMCs. The mature SMCs had SM-MHC and CNN1 assembled into stress 
fibers and were non-proliferative (negative for Ki67) (Fig. 1a-c). By contrast, the SM-MHC− 
cells were smaller, had no SM-MHC, CNN1 or SMA in stress fibers, expressed low level of 
SMA, and were highly proliferative (Fig. 1b-c). After being cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS) for 3 days, the SM-
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MHC− cells started to multiply (Supplementary Fig. S2) and eventually dominated the 
culture.
With the tissue explant culture method, which relies on cell migration, only migratory and 
proliferative cells can be isolated. The cells migrating out of the tunica media expressed 
Ki67 and low levels of SMA, but did not express SM-MHC or CNN1 (Fig. 1d-f). These 
cells had the same characteristics as the SM-MHC− cells isolated by using the enzymatic 
digestion method. In the previous literature, these SM-MHC− cells were defined as synthetic 
and/or proliferative SMCs 21. However, a detailed characterization showed that the SM-
MHC− cells exhibited significant changes in morphology during the culture for an extended 
period. As shown in Supplementary Fig. S3, the size of cell nucleus and the spreading area 
of the cells increased significantly (>3 fold) within a 30-day time period, accompanied by 
the increase of stress fibers (Fig. 1g-i) and the increased expression of SMA and CNN1 (Fig. 
1j-k). These results suggest that the proliferative/synthetic SMCs might be derived from the 
spontaneous differentiation of SM-MHC− cells in the medium with 10% FBS.
To thoroughly characterize these SM-MHC− cells at the early stage (day 3) of primary tissue 
explant culture, we screened protein-marker expression with over 50 antibodies 
(Supplementary Table S1), and found that isolated SM-MHC− cells uniformly expressed 
markers including neural crest cell markers Sox10, Sox1, Snail, vimentin and nestin, 
endoderm marker Sox17, neural cell makers NFM, peripherin, Brn3a, Phox2b and glia cell 
marker S100β (Fig. 1l-s and Supplementary Table S1), and general MSC makers including 
CD29 and CD44 (Fig. 1t, u). In addition, these SM-MHC− cells were negative for CD146 
and Sca-1 (Fig. 1v, w), suggesting that these cells were distinct from previously identified 
perivascular MSC-like cells19 or Sca-1+ progenitors18, 22. These cells were also negative for 
markers for EC and EC conversion-derived MSC-like cells, e.g., CD31/PECAM1 and VE-
cadherin 23, as well as the endothelial progenitor cell (EPC) and hematopoietic stem cell 
(HSC) markers CD34, CD133, c-Kit and Flk-1 (Supplementary Table S1).
To maintain the phenotype of these SM-MHC− cells, we performed screening for 
maintenance medium, and found a modified medium for neural crest stem cell (NCSC) 
culture that could maintain the cell morphology and the expression of aforementioned 
markers in the SM-MHC− cells. The maintenance medium contained DMEM with 2% chick 
embryo extract (CEE), 1% FBS, and 20 ng/ml of basic fibroblast growth factor (bFGF), and 
was used to expand the cells for further analysis.
We further determined whether they were capable of differentiating into ectodermal and 
mesodermal lineages by treating cells with specific differentiation induction media 24–28. 
Indeed, these SM-MHC− cells were capable of differentiating into Schwann cells (positive 
for glial fibrillary acidic protein, GFAP+), peripheral neurons (positive for neuron-specific 
class III β-tubulin, i.e., TUJ1+), SMCs (SM-MHC+), chondrocytes (alcian blue staining), 
adipocytes (oil red staining) and osteoblasts (alizarin red staining) (Fig. 2a-f).
The capability of the SM-MHC− cells differentiation into neural cells was also demonstrated 
in vivo. We isolated SM-MHC− cells from tunica media of carotid arteries of GFP rats, and 
transplanted them into a nerve conduit to bridge transected sciatic nerve as described 25. 
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After 1 month, immunostaining of the longitudinal-sections showed that GFP labeled cells 
differentiated into Schwann cells and contributed to axon myelination, as evident by myelin 
basic protein (MBP) expression (Supplementary Fig. S4).
These results indicate that these SM-MHC− cells in blood vessel wall are multipotent. 
Therefore, we defined these cells as MVSCs. MVSCs could be isolated from the tunica 
media of different blood vessels including jugular vein, aorta, abdominal artery, inferior 
vena cava, femoral artery and femoral vein beside carotid artery (Supplementary Fig. S5), 
but not from adventitia layer, endothelium, or fat tissue around blood vessels by using tissue 
explant culture method.
Single cell cloning and telomerase activity assay
To further confirm the stemness of MVSCs, we performed a cloning assay (Fig. 2g). 
Dilutional cell cloning assay showed that the average plating efficiency of MVSCs was 
about 13%, and the cloned MVSCs retained the marker expression as described in 
Supplementary Table S1, including Sox10, Sox17 (Fig. 2h-i) and other MVSC markers (as 
exemplified in Supplementary Fig. S6a-f), and could self-renew and maintain the 
multipotency (Supplementary Fig. S6g-l). To determine whether MVSCs had the capability 
to form neural spheres as neural crest cells 24, 25, 29, rat MVSCs derived from cloning assay 
were cultured on ultra-low-attachment plates. Indeed, MVSCs formed neural sphere-like 
aggregates (Supplementary Fig. S7a), and the cells within the spheres retained the 
expression of the MVSC markers such as Sox17, vimentin, SMA, nestin and S100β 
(Supplementary Fig. S7b-f).
We then determined whether blood vessels and isolated MVSCs possess telomerase activity. 
Surprisingly, all blood vessels examined had telomerase activity, suggesting the presence of 
stem cells in the vascular wall (Fig. 2j). The isolated MVSCs had a marked increase (>100 
fold) of telomerase activity compared to the respective vascular tissues from which the cells 
were isolated, suggesting the enrichment and purification of stem cells from vascular tissues 
during the cell isolation process. Furthermore, we found no significant difference in 
telomerase activity in MVSCs isolated from different blood vessels.
We used carotid artery and jugular vein as representatives to further compare the MVSCs 
from different blood vessels. DNA microarray showed that MVSCs from carotid arteries and 
jugular veins were almost identical (Fig. 2k), while only 3.6% of genes in expression 
showed significant difference of more than 2-fold (Supplementary Table S2), suggesting 
that MVSCs derived from arteries and veins were similar. DNA microarray also showed that 
MVSCs expressed MSC markers such as CD29, CD44, CD73 and CD90 (Supplementary 
Table S3)
MVSCs did not arise from the de-differentiation of SMCs
Our results suggest that previously identified proliferative/synthetic SMCs could be MVSCs 
and/or their derivatives following spontaneous differentiation in regular culture media. To 
directly determine whether MVSCs were derived from the de-differentiation of mature 
SMCs, we performed lineage tracing by using SM-MHC as a marker in the SM-MHC-Cre/
LoxP-enhanced green fluorescence protein (EGFP) mice 30–32. Immunostaining showed that 
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less than 10% of the cells in the carotid arterial tunica media of SM-MHC-Cre/LoxP-EGFP 
mice were not labeled with EGFP, indicating the existence of a small population of non-
SMCs in the tunica media (Fig. 3a), consistent with the observation in the rat model 
(Supplementary Fig. S1). Immunostaining for Cre and EGFP further showed that the EGFP− 
cells did not express Cre (Supplementary Fig. S8).
With enzymatic digestion culture, majority (about 92%) of the cells isolated from the carotid 
arteries of SM-MHC-Cre/LoxP-EGFP mice were EGFP+ cells (Fig. 3b). However, after 
being cultured and passaged in DMEM with 10% FBS for 10 days, all the cells in culture 
were EGFP− (Fig. 3c), indicating that these cells were not derived from mature SMCs.
In addition, in tissue explant culture, migratory and proliferative cells were EGFP− in 
contrast to strong EGFP fluorescence in the arterial tunica media (Fig. 3d, e). Flow 
cytometry also confirmed that none of the derived vascular cells expressed EGFP, which 
indicated that proliferative and migratory cells isolated from tunica media of blood vessels 
were not derived from the de-differentiation of mature SMCs (Fig. 3f). The lack of EGFP 
expression in MVSCs was unlikely due to the suppression of Rosa26 promoter activity in 
cell culture 33. When SM-MHC-Cre/LoxP-EGFP mice were generated by using β-actin 
(instead of ROSA26) promoter to drive the EGFP expression, tissue explant culture showed 
that cells derived from these mice did not express EGFP, while vascular cells in the tissue 
explant expressed EGFP (Supplementary Fig. S9).
To determine whether these EGFP− cells were similar to rat MVSCs, immunostaining and 
differentiation assay were performed. Immunostaining showed that these EGFP− cells 
uniformly expressed the same MVSC markers including Sox10 (Fig. 3g), Sox17, Sox1, 
Snail, vimentin, S100β and NFM (Supplementary Fig. S10). In addition, these cells could be 
induced to differentiate into Schwann cells (GFAP+/S100β+), peripheral neurons (TUJ1+/
peripherin+), chondrocytes (alcian blue+), adipocytes (oil red+) and osteoblasts (alizarin 
red+) (Fig. 3h-l), which further confirmed that EGFP− cells in tunica media were MVSCs.
To determine whether MVSCs could differentiate into mature SMCs and turn on EGFP 
expression, we activated Notch signaling by co-culturing EGFP− MVSCs with OP9-Delta1 
feeder cells 34. After two weeks of co-culture, majority of the MVSCs showed strong green 
fluorescence (Fig. 3m). Immunostaining for SM-MHC confirmed that MVSCs indeed 
differentiated into SM-MHC+ SMCs (Supplementary Fig. S11a-c). The fact that EGFP 
could be turned on after MVSCs differentiated into SMCs further confirmed that MVSCs 
are not derived from de-differentiation of contractile SMCs. Interestingly, a small portion of 
the EGFP+ cells expressed proliferation marker Ki67 (Supplementary Fig. S11d-f), 
suggesting that newly differentiated SMCs had not exit cell cycle yet.
To test whether MVSCs could differentiate into mature SMCs and turn on EGFP expression 
in vivo, we embedded MVSCs in collagen gel on the outer surface of a nanofibrous vascular 
graft, and implanted the grafts into athymic rats by performing carotid artery 
anastomosis 35, 36. After 1 month, immunostaining of the cross-sections showed that a small 
portion of the cells expressed EGFP, suggesting that MVSCs could differentiate into mature 
SMCs in vivo (Supplementary Fig. S12).
Tang et al. Page 5
Nat Commun. Author manuscript; available in PMC 2013 January 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Previous lineage tracing experiments showed that neural crest cells only contributed to the 
development of carotid artery, aortic arch and large arteries close to the heart 37. To 
determine whether MVSCs from different vascular beds were derived from neural crest, we 
isolated MVSCs from arteries and veins in Wnt1-Cre/LoxP-LacZ mice. MVSCs derived 
from carotid arteries showed positive X-Gal staining while cells derived from jugular veins 
were negative (Fig. 3n-o), indicating that MVSCs are not necessarily derived from the 
neural crest origin.
MVSCs-MSC-SMC differentiation pathway
As shown in Fig. 1g-k, Fig. 2c and Fig. 3m, MVSCs could differentiate into SMCs, and the 
cells at various stages of differentiation could contribute to the heterogeneity of SMCs. It is 
also possible that previously identified MSC-like cells could be derived from MVSCs. 
Therefore, we examined the spontaneous differentiation of MVSCs by culturing the freshly 
isolated MVSCs for 8 weeks in DMEM with 10% FBS.
As shown in Fig. 4a and Fig. 4b, MVSCs were negative for CNN1 and SM-MHC. After 3 
weeks, MVSCs expressed CNN1 but lost the nuclear expression of Sox17 (Sox17−/Sox10+/
CNN1+/SM-MHC−) (Fig. 4c-d). At this stage, the cells lost the capability of differentiating 
into peripheral neurons and Schwann cells, but retained the potential for SMC, ostogenic, 
chondrogenic and adipogenic differentiation, similar to previously reported MSC-like cells. 
These results suggested that MVSCs could be the precursor of MSC-like cells identified in 
blood vessel by previous studies 16, 17, 38.
In addition, after being cultured in DMEM with 10% FBS for 8 weeks, the cells lost the 
expression of Sox17 and Sox10 and spontaneously differentiated into mature SMCs 
(CNN1+/SM-MHC+) (Fig. 4e-f). These cells also lost the differentiation potential into neural 
and mesenchymal lineages (summarized in Fig. 4g). These results suggested that long-term 
culture in the medium containing 10% FBS resulted in the spontaneous differentiation of 
MVSCs into MSC-like cells and subsequently SMCs and that the cells at the various stages 
of differentiation might explain the heterogeneity of SMCs.
Differential response of MVSCs and differentiated cells
MVSCs at different stages of differentiation might respond differently to the same 
stimulation in the vascular microenvironment. To address this issue, we compared the 
effects of three vascular growth factors on undifferentiated MVSCs and MSC-like cells (3-
week differentiation) as an example. The vascular growth factors used in this study included 
bFGF, platelet derived growth factors-B (PDGF-B) and transforming growth factor-β1 
(TGF-β1). PDGF-B and bFGF increased the proliferation of both MVSCs and MSC-like 
cells, while TGF-β1 suppressed the proliferation of MVSCs (Fig. 5a). It was also noted that 
PDGF had more dramatic effect on the proliferation of MSC-like cells compared with 
MVSCs.
Quantitative polymerase chain reaction (qPCR) showed that MSC-like cells had much lower 
expression of MVSC marker such as Sox17 and higher expression of early SMC markers 
such as SMA and CNN1 (Fig. 5b, e, f). bFGF significantly increased Sox17 expression 
while suppressed the expression of SMC markers including SMA and CNN1 of MVSCs 
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(Fig. 5b, e, f), suggesting that bFGF might help maintain MVSCs at undifferentiated state. 
However, bFGF had no significant effect on the expression of Sox17, SMA and CNN1 but 
increased the synthesis of aggrecan (Fig. 5d) in MSC-like cells, suggesting that bFGF might 
promote a synthetic SMC phenotype in MSC-like cells.
PDGF-B also suppressed the expression of SMC markers of MVSCs (Fig. 5e, f), but did not 
show any effect on Sox17 expression (Fig. 5b). In MSC-like cells, PDGF increased 
aggrecan synthesis and CNN1 expression, but had no effect on the expression of SMA (Fig. 
5d-f).
TGF-β1 significantly increased the expression of early SMC markers including SMA and 
CNN1 of MVSCs (Fig. 5e, f), suggesting that TGF-β1 promoted MVSC differentiation into 
SMC lineage. In MSC-like cells, TGF-β1 promoted synthetic SMC phenotype by increasing 
the synthesis of aggrecan (Fig. 5d), similar to bFGF and PDGF. These results demonstrated 
the MVSCs and differentiated cells responded differently to vascular growth factors.
MVSCs activation in vitro and in vivo
Cell proliferation and expansion are important in the development of vascular diseases. 
Therefore, we performed in vitro and in vivo studies to determine the transition of MVSCs 
from quiescent state to proliferative state. We first isolated MVSCs from carotid arteries of 
SD rats by using enzymatic digestion method. Within 24 hours after cell isolation, 
immunostaining showed that MVSCs only expressed low levels of SMA, but not Sox10 or 
Ki67 (Fig. 6a), which indicated that MVSCs were quiescent in the blood vessels. However, 
after being cultured for another 24 hours, MVSCs started expressing Sox10, as well as Ki67 
(Fig. 6b, c), suggesting that MVSCs were activated and became proliferative.
Immunostaining also confirmed that the cells in the normal blood vessel wall did not express 
detectable level of MVSC markers (e.g., Sox10, NFM or S100β) or proliferation marker 
Ki67 (Fig. 6d-f, Supplementary Fig. S13a-f), suggesting that MVSCs were quiescent under 
normal physiological conditions. Upon vascular endothelial denudation injury 39, about 50% 
of cells inside the elastic lamina layers of arterial media were found expressing Sox10 at day 
5 after injury (Fig. 6g-i), and about 40% of Sox10+ cells were positive for proliferative 
marker Ki67 (Fig. 6j-l). The percentage of proliferating cells is similar to what has been 
reported in the previous publications 40–42. The Ki67+ cells were found only in Sox10+ 
MVSC population in tunica media, further confirming that MVSCs instead of SMCs could 
be activated to enter cell cycle upon vascular injury. Of note, we also found Ki67-expressing 
cells in endothelial layer and adventitia layer after injury, indicating that ECs and adventitial 
cells were also activated to enter cell cycle for vascular remodeling. In addition, at day 5 
after injury, the majority of the cells inside tunica media expressed MVSC cytoskeletal 
markers S100β and NFM (Fig. 6m-o), suggesting that MVSCs might have repopulated the 
tunica media following vascular injury and possibly SMC death. The difference in the 
relative percentage of Sox10+ cells and S100β+/NFM+ cells in the tunica media could be 
explained by the difference in the temporal expression of these genes.
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MVSCs instead of SMCs contribute to vascular remodeling
To further investigate the fate of SMCs after vascular injury, we performed endothelial 
denudation injury in the carotid artery of SM-MHC-Cre/LoxP-EGFP mice. Immunostaining 
showed that the cells in native carotid artery express EGFP but not MVSC marker S100β 
(Fig. 7a-c). Surprisingly, at day 5 after injury, the majority of the cells in tunica media 
expressed S100β instead of EGFP (Fig. 7d-f), which is consistent with previous notion that 
most SMCs may die by apoptosis while remaining cells proliferate and repopulate tunica 
media after vascular injury 43, 44. Although a low number of EGFP+ cells were found at this 
time point, none of them expressed proliferation marker Ki67 (Supplementary Fig. S14), 
which further confirmed that mature SMCs were not able to de-differentiate to entry cell 
cycle. Thus, MVSCs, rather than SMCs, were activated and proliferated rapidly to 
repopulate the tunica media after injury and contributed to vascular remodeling.
The neointima formation was observed around day 15 after endothelial denudation injury in 
rat carotid arteries. Majority of the cells in the tunica media and neointima expressed MVSC 
makers including Sox10, NFM and S100β at day 15 and 30 (Fig. 7g-l; Supplementary Fig. 
S13g-l), indicating that MVSCs were the major cell type in tunica media and neointima after 
vascular remodeling. In addition, the percentage of Ki67+ MVSCs inside the neointima was 
32% at day 15, and decreased to less than 1% at day 30, suggesting a transient expansion of 
MVSCs in the vascular wall. Furthermore, around day 30, most of S100β+ cells also 
expressed SM-MHC (Fig. 7m-o) and some of the cells were still proliferating, which is 
consistent with the in vitro observation (Supplementary Fig. S11d-f) that the newly 
differentiated SM-MHC+ cells might have not exit cell cycle yet.
At 1 month post injury, alcian blue staining and Verhoeff’s staining showed significant 
deposition of aggrecan and collagen I respectively in neointima populated by MVSCs (Fig. 
8a; Supplementary Fig. S15a), suggesting that MVSCs-derived cells had synthetic 
phenotype and contributed to the matrix synthesis during neointima formation. 
Immunostaining showed that some of the MVSCs in neointima differentiated into 
chondrogenic cells (S100β+/collagen II+) (Supplementary Fig. S15b), which demonstrated a 
novel mechanism of ectopic cartilage tissue formation in the injured blood vessels.
To determine whether there were still undifferentiated MVSCs in neointima, we isolated 
cells from neointima tissue 1 month after injury by using the explant culture method. Indeed, 
cells with same marker expression and differentiation potential as MVSCs could be derived 
from neointima tissues (Fig. 8b-i), suggesting that MVSCs were capable of self-renewal in 
vivo during vascular remodeling.
MVSCs exist in human blood vessels
To test whether MVSCs exist in human blood vessels, we used human carotid artery as a 
representative and characterized the cells isolated by tissue explant culture. Indeed, MVSCs 
could be isolated from human arteries, and the cells expressed MVSC markers such as 
Sox10, Sox17, Pax-3/7, vimentin, NFM and S100β (Fig. 8j-o). Similar to rodent MVSCs, 
human MVSCs can be induced to differentiate into Schwann cells, neuronal cells, SMCs, 
chondrocytes and adipocytes (Supplementary Fig. S16).
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Discussion
The identification of MVSCs brings a new perspective on vascular remodeling and disease 
development. Our in vitro experiments suggest that proliferative/synthetic SMCs are derived 
from the differentiation of MVSCs instead of the de-differentiation of mature SMCs. In vivo 
experiments also demonstrate that MVSCs, rather than mature SMCs, repopulate the tunica 
media and form neointima after endothelial denudation injury. These results provide the first 
direct evidence to support the MVSC differentiation hypothesis and disprove the SMC de-
differentiation theory. The fact that highly expandable and migratory MVSCs were not 
derived from mature SMCs suggests that the previously reported decrease of contractile 
markers in SMC culture in vitro or after vascular injury in vivo could be attributed to the 
rapid expansion of MVSCs and their spontaneous differentiation into immature SMCs. 
MVSCs not only proliferate and differentiate, but also become synthetic and secrete matrix 
proteins such as collagen I, collagen II and aggrecan. The multipotential of MVSC 
differentiation into SMCs, chondrogenic cells and other lineages offers a novel and 
reasonable explanation for the complex phenotypes of cells in the diseased vessel.
MVSCs at different stages of differentiation could also explain the heterogeneity of SMC in 
culture and in vivo. The fact that MVSCs and their derivatives respond differently to 
vascular growth factors underscores the importance of characterizing the cell culture from 
blood vessels. In the literature, the differentiation stage of “SMCs” is usually not well 
characterized. For example, the cells positive for SMA, SM-22α and CNN1 are often treated 
as SMCs rather than immature SMCs or partially differentiated MVSCs. In many studies, 
the cells in culture may not be homogeneous at a specific differentiation stage, which may 
result in conflicting observations and explanation. Previous studies have identified a 
subpopulation of SMCs, termed “epithelioid” cells, from newborn or injured vessels 45–48. 
The origin of these SMCs is not known, and the relationship of “epithelioid” cells with 
vascular stem cells has not been explored. It is very likely that “epithelioid” SMCs are 
derived from MVSCs. However, in adults, MVSCs can be isolated from both normal vessels 
and injured vessels, but “epithelioid” SMCs are only derived from injured vessels. It is 
possible that dormant MVSCs are a small population in normal vessels and may be 
overlooked.
In addition to proliferative/synthetic SMCs, MVSCs could differentiate into mature SMCs 
(SM-MHC+) in vitro and in vivo. It is also worth noting that the extent of MVSC activation, 
proliferation and differentiation could be dependent on the extent of vascular injury and 
SMC damage 42. However, a recent study using SM-MHC as a marker for lineage tracing 
demonstrates that neointima is populated by proliferative cells derived from mature SMCs at 
3 weeks following vascular injury 49. This apparent discrepancy has two possible 
explanations. Firstly, these proliferating cells could be derived from MVSCs after such a 
long time period. Indeed we have shown that newly differentiated SMCs (SM-MHC+) may 
not have exited the cell cycle completely (Supplementary Fig. S11d-f). In addition, at an 
earlier time point (e.g., within a week), we never detected proliferating cells positive for 
SM-MHC (Fig. 1c). Secondly, the two transgenic mouse lines of SM-MHC-Cre used for the 
lineage tracing of SMCs were generated independently 30, 50. We cannot exclude the 
possibility that a subtle difference in the promoter of SM-MHC in these two mouse lines 
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exists. Although both mouse lines have been verified with extensive characterization and 
should be appropriate for tracing the fate of mature SMCs, further studies are needed to 
directly compare these mouse lines. Another study on the lineage tracing of SMCs shows 
that SMCs give rise to osteogenic and chondrogenic cells in arteries17. However, SM22α 
instead of SM-MHC was used as the marker for lineage tracing in this study. Since SM22α 
is also expressed in MVSCs and their derivatives, this study may not distinguish the source 
of the cells between MVSCs and SMCs.
Another important finding is that MVSCs are the cell type in tunica media that can be 
activated by vascular injury to proliferate and participate in remodeling. Neointima cells 
have a large cell body, secrete extra-cellular matrix (ECM) and express lower levels of the 
smooth muscle-specific contractile proteins 51, which is consistent with our findings on the 
changes of cell morphology and the expression of SMC markers during the spontaneous 
differentiation of MVSCs. In this study, we showed that MVSCs, instead of SMCs, are the 
major cell type in neointimal tissue as characterized by MVSC makers. Given the fact that 
some MVSCs in neointima still retain multipotency, it is reasonable to propose that aberrant 
activation, expansion and differentiation of MVSCs may contribute to not only SMC 
differentiation and cartilage formation but also many other aspects of vascular diseases such 
as fat and cholesterol metabolism, matrix remodeling and calcification. Since the rodent 
model of denudation injury does not result in significant fat and cholesterol accumulation 
and intima calcification, the possibility of MVSC differentiation into adipogenic and 
osteogenic cells in diseased vessels remains to be tested by using atherosclerosis models. 
The identification of MVSC in human arteries makes MVSC a potential therapeutic target of 
vascular diseases.
MVSCs in arteries and veins may have different developmental origins. Wnt1 lineage 
tracing experiments suggest that MVSCs in carotid arteries may be neural crest origin. In 
contrast, for blood vessels not developed from neural crest (e.g., jugular vein), MVSCs are 
negative for Wnt1. It is possible that these MVSCs are derived from other germ layers such 
as mesoderm. Nevertheless, MVSCs from carotid arteries and jugular veins have similar 
gene expression profile, suggesting that MVSCs in different vascular beds, regardless of 
their developmental origins, may share similar characteristics. In addition, MVSCs are 
different from NCSCs because MVSCs do not express some NCSC markers such as p75, 
HNK1, Slug or AP2 25, 52–54.
To date, MVSCs are a unique precursor identified for adult MSCs and MSC-like cells, and 
MSC precursors similar to MVSCs likely exist in many other tissues. MVSCs express CD29 
and CD44, two non-specific surface markers of MSCs and SMCs. However, there was no 
specific marker, especially no transcriptional factor marker, for MSCs. In this study, we 
have identified several transcriptional markers and cytoskeletal markers in MVSCs, such as 
Sox17, Sox10, nestin, NFM and S100β. In addition, we showed that MSC-like cells were 
also positive for some of these markers (except Sox17). These results provide insight into 
the characteristics of MVSCs and MSC-like cells, not only in blood vessels, but also in other 
tissue types.
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This study supports a new hypothesis that MVSC activation and differentiation instead of 
SMC de-differentiation results in the proliferative and synthetic cells in the vascular wall, 
and that the aberrant activation and differentiation of MVSCs may have an important role in 
the development of vascular diseases. These findings provide unprecedented insight into the 
role of stem cells in vascular diseases and remodeling, which suggests that vascular diseases 
are stem cell diseases. These findings may have transformative impact on vascular biology 
and diseases, and may lead to new therapies by using MVSCs as a therapeutic target.
Methods
Generation of transgenic mice and genotyping
Animal studies were approved by the ACUC committee at UC Berkeley, and were carried 
out according to the institutional guidelines. Transgenic mice, expressing Cre recombinase 
under the control of the SM-MHC promoter were mated with transgenic mice with a 
construct of Rosa26-LoxP-EGFP or Actin-LoxP-EGFP (Jackson laboratory, Inc.) to 
generate SM-MHC-Cre/LoxP-EGFP mice. Transgenic mice, expressing Cre recombinase 
under the control of the Wnt1 promoter were mated with Rosa26-LoxP-LacZ mice to 
generate Wnt1-Cre/LoxP-LacZ mice. Genotyping was performed with polymerase chain 
reaction (PCR) by using total DNA extracted from mice tail tissues as described 
previously 3031, 55. The sequences of primers used for genotyping were shown in 
Supplementary Table S4.
Cell isolation
Cells were isolated from the blood vessels in rat, mouse and human. Human carotid arteries 
were obtained from National Disease Research Interchange (Philadelphia, PA). The cells 
isolation methods were described previously 56. Briefly, the tissue segments were washed 
three times with phosphate buffered saline (PBS) supplemented with 1% penicillin/
streptomycin (P/S). The surrounding connective tissues and adventitia were dissected away 
under a dissecting microscope. Endothelium was removed by scraping off the cell layer on 
the luminal surface with sterile scalpel blades. For tissue explant culture method, the tunica 
media was cut into mm-size and placed onto the surface coated with 1% CellStart 
(Invitrogen Corp.) in 6-well plates. The cells were cultured in DMEM with 10% FBS 
(Thermo Fisher Scientific Inc.), or in DMEM with 2% CEE (MP Biomedical, Inc.), 1% 
FBS, 1% N2 (Invitrogen Corp.), 2% B27 (Invitrogen Corp.), 100 nM retinoic acid (RA) 
(Sigma-Aldrich, Inc.), 50 nM 2-mercaptoethanol (2ME) (Sigma-Aldrich, Inc.), 1% P/S and 
20 ng/ml bFGF (R&D Systems, Inc.) (Maintenance medium). For enzymatic digestion 
methods, tissues were incubated with 3 mg/ml type II collagenase (Sigma-Aldrich Inc.) in 
DMEM with a 1/5 (w/v) ratio of tissue (g) to enzyme solution (ml). After incubation at 37°C 
for 30 min, the same volume of 1 mg/ml elastase (Sigma-Aldrich, Inc.) solution was added 
to the solution containing the tissue and collagenase. The tissues were incubated for another 
1–2 hours until all the tissues were digested. Cells were then seeded onto CellStart-coated 
dishes and maintained at 37°C in an incubator with 5% CO2.
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Cell cloning assays
For the clonal assays, MVSCs were detached, and the cells were resuspended with 
maintenance medium and filtered through membranes with 40-µm pore size to obtain single 
cells. Filtered cells were seeded onto CellStart-coated 96-well plates at the clonal density (1 
cell/well) and cultured for 3 weeks at 37°C in an incubator with 5% CO2.
Sphere formation and differentiation assays
For sphere formation assay, cell suspension was plated onto ultra-low-attachment 6-well 
plates (Corning, Inc.) at the density of 0.5 × 106 cells/well in the presence of maintenance 
medium for 1 week. The derived neural sphere-like aggregates were collected and embedded 
into OCT compound (Tissue Tek Inc.) for cryosectioning and immunostaining.
For the directed differentiation of MVSCs into peripheral neurons, Schwann cells, 
osteoblasts, adipocytes and chondrocytes, the cells were incubated in specific induction 
media described previously for 1–3 weeks 24, 25.
Telomerase activity assay
Telomerase activities of MVSCs and the tissues from which the cells were isolated were 
measured by using telomeric repeats amplification protocol (TRAP) combined with real-
time detection of amplification products using a Quantitative Telomerase Detection kit (US 
Biomax Inc.) according to the instruction of the manufacturer. Total protein extract (0.5 µg 
for each sample) was used in each reaction. Real-time polymerase chain reaction (PCR) 
analysis was performed by using an ABI PRISM 7000 Sequence Detection System. The 
amount of molecules was quantified by using the standard curve, and normalized with the 
level of α-actin in each sample measured by an ELISA kit (Cell Signaling Technology, 
Inc.).
Growth factor treatment and cell proliferation assay
Undifferentiated MVSCs and partially differentiated MVSCs (cultured in DMEM with 10% 
FBS for 3 weeks) were starved in DMEM with 1% FBS for 24 hours followed by the 
treatment of 10 ng/ml bFGF (Peprotech, Inc.), 10 ng/ml PDGF-B (Peprotech, Inc.) or 10 
ng/ml TGF-β1 (Peprotech, Inc.) for another 24 hours. The cell proliferation was quantified 
by using Click-iT EdU Alexa Fluor 488 HCS Assay kit (Invitogen Corp.) according to the 
instruction of the manufacturer.
RNA isolation for oligonucleotide microarray and qPCR
MVSCs derived from carotid arteries and jugular veins of SD rats were lysed with Trizol 
reagent (Invitrogen Corp.) and total RNA was extracted as previously described 36. For 
microarray analysis, the RNA pellet was resuspended in nuclease-free H2O and was 
subsequently diluted to a concentration of 0.50 mg/ml. Then, 10 µl of each sample was used 
for the analysis by using an Affymetrix oligonucleotide microarray U133AA of Av2 chip 
containing 31099 probe sets. Samples were labeled and hybridized according to Affymetrix 
protocols. Signal intensities were obtained for all probe sets and were organized by using 
GeneTraffic version 3.2 microarray analysis software (Iobion LLC).
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For qPCR, RNA pellets were resuspended in diethyl pyrocarbonate (DEPC)-treated H2O. 
cDNA was synthesized by using two-step reverse transcription with the ThermoScript RT-
PCR system (Invitrogen, Inc), followed by qPCR with SYBR green reagent and the ABI 
Prism 7000 Sequence Detection System (Applied Biosystems). The sequences of the 
primers used in this study are shown in Supplementary Table S5.
Carotid artery endothelial denudation model
The rat and mouse carotid arteries were subjected to endothelial denudation injury as 
described previously 39. Briefly, adult SD rats or transgenic mice were anesthetized with 
isoflurane. Endoluminal injury to the left common carotid artery was produced by custom-
made wire probes that consisted of a 10-cm-long stainless steel wire soldered with a copper-
beaded tip. Rats or mice were sacrificed at 5, 15 and 30 days after injury, with at least 6 
animals for each time point. The blood vessels samples were rinsed with PBS and embedded 
in OCT compound for histological analysis.
In vivo transplantation
Electrospinning technique was used to produce vascular grafts and nerve conduits as 
previously described 25, 35, 36, 57. For cell transplantation into nerve conduits, MVSCs were 
isolated by using tissue explant culture method from the carotid arteries of GFP rats. The 
cell suspension was mixed with cold matrigel solution at a 2:1 ratio (volume to volume), and 
injected into the nerve conduits. The tissue-engineered constructs were kept in the incubator 
for 1 hour to allow gelation. The nerve conduit was inserted between the two nerve stumps 
and sutured, creating a gap of 1 cm between the two stumps.
For the transplantation of MVSCs into microfibrous vascular grafts, MVSCs were derived 
from the carotid arteries of MHC-Cre/LoxP-EGFP mice by using the tissue explant culture 
method. MVSCs were mixed with neutralized collagen solution (2 mg/ml; diluted in MVSC 
maintenance medium), resulting a cell density at 1 million cells/0.5 ml. The collagen gel 
solution (with cells) was then used to fill in the space outside of the vascular graft in a 1-ml 
syringe and allowed to polymerize at 37°C for 1 hour. Then DMEM with 10% FBS 
containing 10 ng/ml TGF-β1 was added into the syringe to cover the grafts. After 1-day 
culture, the gel was contracted by the embedded cells and attached tightly onto the outer 
surface of the graft. The vascular grafts with cells were then transplanted into athymic rats 
by using carotid artery anastomosis.
Staining and histological analysis
For immunostaining, cells or the tissue sections of blood vessels were fixed with 4% PFA, 
permeabilized with 0.5% Triton-100 (Sigma-Aldrich, Inc.), and blocked with 1% bovine 
serum albumin (BSA) (Sigma-Aldrich, Inc.). For actin cytoskeleton staining, samples were 
incubated with fluorescein isothiocyanate (FITC)-conjugated phalloidin (Invitrogen Corp.) 
for 30 min to stain filamentous actin (F-actin). For the staining of other cell markers, 
samples were incubated with specific primary antibodies (Supplementary Table S1) for 2 
hours at room temperature, washed with PBS for 3 times, and incubated with appropriate 
Alexa 488- and/or Alexa 546-labeled secondary antibodies (Molecular Probes, Inc.). Nuclei 
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were stained with DAPI (Invitrogen Corp.). Fluorescence images were collected by a Zeiss 
LSM710 confocal microscope.
For organic dye staining, cells or the tissue sections were fixed with 4% PFA for 30 min, 
washed and stained with alizarin red (Sigma-Aldrich, Inc.), alcian blue (Sigma-Aldrich, 
Inc.), oil red (Sigma-Aldrich, Inc.) or Verhoeff’s dye (American MasterTech, Inc.) 
according to the instruction of the manufacturers. Images were collected by a Zeiss 
Axioskop 2 plus microscope.
Flow cytometry analysis
For flow cytometry analysis, cells were dissociated after the exposure to 0.2% EDTA for 20 
min at room temperature. The cells in suspension were blocked with 1% BSA, incubated 
with specific primary antibodies, and then stained with secondary antibodies. Negative 
control sample was incubated with a non-specific antibody with the same isotype as the 
specific primary antibody, and stained with the same secondary antibody. 7-AAD (BD 
Pharmingen Inc.) was used to exclude dead cells. Cells were analyzed by using FACScan 
flow cytometer (Becton Dickinson Inc.) and FlowJo software (Tree Star, Inc.).
Statistics
Data were reported as means ± standard deviation, unless otherwise indicated. All 
experiments were repeated at least three times. Comparisons among values for all groups 
were performed by one-way analysis of variance (ANOVA). Holm’s t test was used for the 
analysis of differences between different groups. Significance level was set as p<0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Characterization of SM-MHC− cells isolated from rat carotid arterial tunica media
(a-c) Cells were isolated from arterial tunica media by using enzymatic digestion method. 
The derived cells were immunostained for SMA, SM-MHC, CNN1 and Ki67 after being 
cultured in DMEM with 10% FBS for 3 days. Arrow in b indicates a SM-MHC− cell. 
Arrows in c indicate proliferating SM-MHC− cells in culture. Arrowhead in c indicates a 
non-proliferative mature SMC. (d-f) Cells were isolated from arterial tunica media by using 
tissue explant culture method. The derived cells were immunostained for SMA, Ki67, SM-
MHC and CNN1 after being cultured in DMEM with 10% FBS for 3 days. (g-k) SM-MHC− 
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cells were cultured in DMEM with 10% FBS for 5, 15 and 30 days, and either subjected to 
FITC-phalloidin staining for F-actin (g-i) (Nuclei were stained with DAPI) or used for qPCR 
to measure the gene expression of SMA and CNN1 (j-k). 18S rRNA was used to normalize 
the relative expression levels. Data were shown as average ± standard deviation (n=3). * 
indicates significant difference between indicated groups by using Holm’s t-test. (p<0.01). 
(l-s) Immunostaining of isolated SM-MHC− cells cultured in DMEM with 10% FBS for 3 
days for various markers, including Sox10, Sox17, Sox1, Snail, vimentin, nestin, S100β and 
NFM. (t-w) Flow cytometry analysis of SM-MHC− cells derived from arterial tunica media 
cultured in DMEM with 10% FBS for 3 days with antibodies against CD29, CD44, CD146 
and Sca-1. Filled grey curves represent negative control samples, red curves represent 
samples stained with antibodies for CD29 (t), CD44 (u), CD146 (v) or Sca-1 (w). Scale bars 
are 100 µm.
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Figure 2. Differentiation assay, single cell cloning and telomerase activity assay of SM-MHC− 
cells derived from rat carotid arterial tunica media
(a-f) Staining of differentiated cell derived from SM-MHC− cells: Schwann cells for GFAP 
(a), neurons for TUJ1 (b), SMCs for SM-MHC (c), chondrocytes for aggrecan by using 
alcian blue (d), adipocytes for lipid droplets by using oil red (e) and osteoblasts for calcified 
matrix by using alizarin red (f). Scale bars of a-c are 50 µm. Scale bars of d-f are 100 µm. (g) 
Schematic illustration of single cell cloning with maintenance media. (h-i) Immunostaining 
of cloned MVSCs for Sox10 and Sox17. (j) Telomerase activity assay of MVSCs and the 
tissues from which MVSCs were isolated. The data was shown as average ± standard 
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deviation (n=3). White bars indicate tissues and black bars indicate isolated MVSCs. * 
indicates significant difference between MVSCs and the tissue from which the cells were 
derived by using Student’s t-test (p<0.05). † indicates significant difference between inferior 
vena cava and other blood vessels by using Holm’s t-test (p<0.05). AO: aorta, CA: carotid 
artery, JV: jugular vein, AA: abdominal artery, IVC: inferior vena cava, FA: femoral artery, 
FV: femoral vein. (k) DNA microarray analysis of MVSCs derived from rat carotid arteries 
and jugular veins (n=3).
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Figure 3. Characterization of MVSCs derived from mouse blood vessels by using lineage tracing 
model with SM-MHC and Wnt1 as markers
(a) A cross-section of carotid artery from SM-MHC-Cre/LoxP-EGFP mouse was 
immunostained for EGFP (green) and SMA (red). The arrow indicates a SM-MHC− cell 
inside tunica media. Scale bar is 50 µm. (b-c) Flow cytometry analysis for EGFP of cells 
derived from carotid arteries of SM-MHC-Cre/LoxP-EGFP mice by using enzymatic 
digestion method at day 0 (b) (n=3) and day 10 (c) (n=3), with the cells cultured in DMEM 
with 10% FBS . (d-e) Phase contrast and fluorescent images of tissue explant culture of 
carotid arterial tissue from SM-MHC-Cre/LoxP-EGFP mice. Scale bars are 100 µm. (f) 
Flow cytometry analysis for EGFP expression in the cells derived in d-e (n=6). (g) 
Immunostaining of the EGFP− cells derived from carotid arteries of SM-MHC-Cre/LoxP-
EGFP mice for Sox10. Scale bar is 100 µm. (h-l) Staining of differentiated cells derived 
from EGFP− cells: Schwann cells for GFAP and S100β (h), neurons for TUJ1 and peripherin 
(i), chondrocytes for aggrecan by using alcian blue (j), adipocytes for lipid droplets by using 
oil red (k) and osteoblasts for calcified matrix by using alizarin red (l). Scale bars of i-j are 
50 µm. Scale bars of k-m are 100 µm. (m) EGFP expression in MVSCs after being co-
cultured with OP9-Delta1 cell line for 2 weeks. Scale bar is 50 µm. (n-o) X-Gal staining of 
MVSCs derived from carotid arteries (n) and jugular veins (o) of Wnt1-Cre/LoxP-lacZ 
mouse. Scale bars are 50 µm.
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Figure 4. Spontaneous differentiation of MVSCs into MSC-like cells and SMCs
(a-f) MVSCs were cultured in DMEM with 10% FBS for 5 (a-b), 3 weeks (c-d) and 8 weeks 
(e-f), and were immunostained for Sox17, CNN1, SM-MHC and Sox10. Scale bar is 100 
µm. The nuclei were stained with DAPI. (g) Schematic illustration of the spontaneous 
differentiation of MVSCs and the differentiation potential of the cells at different stages.
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Figure 5. Differential response of MVSCs and MSC-like cells to the treatment of vascular 
growth factors
The undifferentiated MVSCs (cultured in DMEM with 10% FBS for 5 days) and MSC-like 
cells (cultured in DMEM with 10% FBS for 3 weeks) were treated with 10 ng/ml bFGF, 10 
ng/ml PDGF-B or 10ng/ml TGF-β1 for 24 hours. White bars indicate undifferentiated 
MVSCs and black bars indicate MSC-like cells. (a) EdU staining was used to quantify the 
proliferating cells. (b-f) Quantitative PCR analysis was used to quantify the gene expression 
of Sox17 (b), Sox10 (c), aggrecan (d), SMA (e) and CNN1 (f). 18S rRNA was used to 
normalize the relative expression levels. Data were shown as average ± standard deviation 
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(n=3). * indicates significant difference between growth factors-treated and untreated 
MVSCs by using Holm’s t-test (p<0.05). † indicates significant difference between growth 
factor-treated and untreated MSC-like cells by using Holm’s t-test (p<0.05). ‡ indicates 
significant difference between MVSCs and MSC-like cells in absence of growth factors by 
using Student’s t-test (p<0.05).
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Figure 6. MVSC activation in vitro and in vivo
(a-c) MVSCs were isolated from rat carotid arteries by using enzymatic digestion method, 
and cultured in DMEM with 10% FBS for 24 hours (a) and 48 hours (b-c). The cells were 
immunostained for SMA, Ki67 and Sox10. Scale bar is 100 µm. (d-l) Immunostaining of 
cross-sections from native carotid arteries (d-f) and injured carotid arteries (day 5) (g-o) with 
the antibodies against Sox10, SMA, Ki67, S100β and NFM. A: Adventitia, L: Lumen, M: 
Media. The nuclei were stained with DAPI. Scale bars are 50 µm.
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Figure 7. MVSCs instead of SMCs contributed to vascular remodeling and neointima formation 
after endothelial denudation injury
(a-f) Immunostaining of cross-sections of native carotid arteries (a-c) and injured carotid 
arteries (day 5) (d-f) from SM-MHC-Cre/LoxP-EGFP mice with the antibodies against 
EGFP and S100β. (g-l) Immunostaining of cross-sections from carotid arteries of SD rats at 
day 15 after injury with the antibodies against Sox10, Ki67, S100β and NFM. (m-o) 
Immunostaining of cross sections of carotid arteries from SD rats at day 30 after injury with 
the antibodies against S100β and SM-MHC. Scale bars are 50 µm. The nuclei were stained 
with DAPI. A: adventitia, I: intima, L: lumen, M: media.
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Figure 8. Characterization of MVSCs from neointima in rat and MVSCs from normal human 
carotid artery
(a) Alcian blue staining of a cross-section of carotid artery from SD rat at week 5 after 
injury. Square indicates the area where the cells were isolated. Scale bar is 50 µm. (b-c) The 
cells isolated from neointima in rat were stained for MVSC markers Sox10 and Sox17. Scale 
bars are 50 µm. (d-i) The cells isolated from neointima were subjected to differentiation 
assays and stained for SMC markers SM-MHC and CNN1 (d), Schwann cell markers GFAP 
and S100β (e), neuronal marker TUJ1 and peripherin (f), aggrecan in chondrogenic culture 
by using alcian blue (g), oil droplets in adipogenic culture by using oil red (h), and calcified 
matrix in osteoblastic culture by using alizarin red) (i). Scale bars of d-f are 50 µm. Scale 
bars of g-i are 100 µm. (j-o) Immunostaining of MVSCs isolated from human carotid 
arteries with antibodies against Sox10, Sox17, Pax-3/7, vimentin, NFM and S100β. Scale 
bars are 100 µm.
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